Copp comes to the company from McKinsey & Co.
Ceribell announced that it has named Joshua Copp as its new chief operating officer.
In a press release, Ceribell co-founder and CEO Jane Chao, PhD, said, “Joshua's leadership within McKinsey & Co.'s Medical Device Division provides him with a wealth of expertise that he will now bring to our team. His professional experience driving growth and shaping markets with clients aligns seamlessly with Ceribell's vision to make Ceribell the standard of care in seizure management."
Ceribell developed an AI-powered point-of-care EEG diagnostic system and is working to improve seizure management in acute care.
PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.